Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions
NCT ID: NCT05851079
Last Updated: 2023-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
15000 participants
OBSERVATIONAL
2021-12-10
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* High-throughput HPV typing and integrated assays can screen for ≥ cervical intraepithelial neoplasia (CIN2 or CIN3) with high sensitivity and accuracy.
* High-throughput HPV typing and integrated assays can be promoted as a screening tool for cervical cancer.
Participants will be screened with routine screening protocols (Cobas HPV test combined with TCT test), and if the results are abnormal, colposcopy and cervical biopsy will be performed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women
NCT05570331
Comparison of Screening Tests in Detecting Cervical Neoplasia
NCT00039312
Effect of HPV Integration on Prognosis of Young Women With CIN2 in China
NCT05282095
HPV Integration Testing for Cervical Cancer Screening
NCT02576158
iMproving thE DIagnostics And Treatment Of ceRvical Precancer
NCT05870787
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Relying on the project's clinical multicenter to recruit patients for routine HPV screening in hospital outpatient clinics, for HPV high-risk type-positive subjects. The subjects with positive HPV types will continue to undergo TCT and colposcopic biopsy, and the remaining specimens after routine screening will be collected for high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods.
2. Parallel experimental design:
A multicenter cohort of 12,000 permanent residents was recruited for routine cervical cancer screening(HPV+TCT combined screening), and the remaining specimens were collected after the conventional screening to test the indexes of high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods.
3. Prospective cohort study design:
Based on a multicenter cohort of cervical cancer screening based on the project group, 3000 cervical cancer patients with HPV-positive routine screening and colposcopic biopsies were enrolled. The cohort was followed up regularly for 3 years with routine HPV+TCT and colposcopy, and cervical biopsy if necessary. And specimens remaining after routine screening will be collected for testing of high-throughput HPV typing and integrated assays.
4.subject selection:
1. .Stratified study design subjects were selected from patients who were first screened for cervical cancer in hospital outpatient clinics.
2. .Parallel trial design subjects were selected from resident female residents in a cohort of cervical cancer screening established by a clinical center.
3. .The prospective cohort study was designed to include HPV-positive patients in the cohort of cervical cancer screening established by the clinical center and whose cervical lesions were excluded by colposcopic biopsy.
5.This project is a multicenter prospective cohort study to investigate the immediate, 1st year, 2nd year and 3rd year cumulative risk of developing CIN2+ and CIN3+ in HPV 16 or 18-positive patients with positive and negative test results by integrating test results through a logistic Weibull model to assess whether colposcopy can be delayed and thus serve as a cervical cancer screening triage by comparing with risk values and clinical thresholds in the 2019 American Society for Colposcopy and Cervical Pathology(ASCCP)guidelines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. Stratified experimental design
Relying on the project's clinical multicenter to recruit patients for routine HPV screening in hospital outpatient clinics, for HPV high-risk type-positive subjects. The subjects with positive HPV types will continue to undergo TCT and colposcopic biopsy, and the remaining specimens after routine screening will be collected for high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods.
TCT test
These tests were performed on cervical exfoliated cells.
Vaginoscopy
To obtain the results of the patient's pathology report.
High throughput HPV typing and integration detection methods
This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
Cobas HPV test
To obtain HPV typing results.
2. Parallel experimental design
A multicenter cohort of 12,000 permanent residents was recruited for routine cervical cancer screening(HPV+TCT combined screening), and the remaining specimens were collected after the conventional screening to test the indexes of high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods.
TCT test
These tests were performed on cervical exfoliated cells.
High throughput HPV typing and integration detection methods
This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
Cobas HPV test
To obtain HPV typing results.
3. Prospective cohort study design:
Based on a multicenter cohort of cervical cancer screening based on the project group, 3000 cervical cancer patients with HPV-positive routine screening and colposcopic biopsies were enrolled. The cohort was followed up regularly for 3 years with routine HPV+TCT and colposcopy, and cervical biopsy if necessary. And specimens remaining after routine screening will be collected for testing of high-throughput HPV typing and integrated assays.
TCT test
These tests were performed on cervical exfoliated cells.
Vaginoscopy
To obtain the results of the patient's pathology report.
High throughput HPV typing and integration detection methods
This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
Cobas HPV test
To obtain HPV typing results.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TCT test
These tests were performed on cervical exfoliated cells.
Vaginoscopy
To obtain the results of the patient's pathology report.
High throughput HPV typing and integration detection methods
This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
Cobas HPV test
To obtain HPV typing results.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. History of sexual intercourse.
Exclusion Criteria
2. History of cervical treatment;
3. Age \<25, \>70 years;
4. Pregnancy.
25 Years
70 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuhan Central Hospital
OTHER
Tongji Hospital
OTHER
Women's Hospital School Of Medicine Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hui Wang, PhD
Role: PRINCIPAL_INVESTIGATOR
Women's Hospital School Of Medicine Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Women's hospital school of medicine zhejiang university
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-20210333-R
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.